Global Acromegaly and Gigantism Drugs research
Global Acromegaly and Gigantism Drugs research

Acromegaly and Gigantism Drugs Comprehensive Study by Type (Somatostatin Analogs, GH Receptor Antagonists, Dopamine Agonists, Recombinant Human IGF-1), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies) Players and Region - Global Market Outlook to 2026

Acromegaly and Gigantism Drugs Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

May 2021 Edition 236 Pages 173 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Industry Background:
Acromegaly is a hormonal condition caused by excessive growth hormone (GH) release. Adults are affected. Acromegaly is usually caused by a pituitary tumor. Acromegaly refers to the growth of the hands and feet. Gigantism is also a hormonal disorder characterized by excessive growth hormone release and production during childhood. Overgrowth of the bones and excessive height are common symptoms of this condition. Acromegaly and gigantism are both considered dangerous disorders that can be fatal. Both Gigantism and Acromegaly are pituitary gland illnesses with aberrant hormone releases. To address these illnesses, a variety of therapeutic options are available, including medications, surgery, and radiation therapy. The key market drivers for Acromegaly and Gigantism Treatment Market are an increase in the incidence of chronic diseases as well as an increase in the number of hormonal abnormalities.This growth is primarily driven by Rising Prevalence of Chronic Diseases, Increasing Various Hormonal Disorders and Rise in Awareness Among People About Diagnosis of the Disease.

Globally, a noticeable market trend is evident Growing Popularity of Drugs Over Surgeries. Major Players, such as Pfizer Inc (United States), Novartis AG (Switzerland), Chiasma Inc (United States), Ipsen Pharma (France), Johnson and Johnson (United States), F. Hoffmann -La Roche Ltd (Switzerland), Takeda Pharmaceutical Company Limited (Japan), Zydus Pharmaceuticals (United States), Peptron (South Korea) and Hikma Pharmaceuticals PLC (United Kingdom) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

June 2020- The US Food and Drug Administration (FDA) has approved oral octreotide (Mycapssa, Chiasma) delayed-release capsules for the long-term maintenance treatment of patients with acromegaly

Market Drivers
  • Rising Prevalence of Chronic Diseases
  • Increasing Various Hormonal Disorders
  • Rise in Awareness Among People About Diagnosis of the Disease

Market Trend
  • Growing Popularity of Drugs Over Surgeries

Restraints
  • Side Effects of Certain Drugs

Opportunities
Increased Investment on R&D in Development of New Drugs and Technological Advancements
Challenges
Stringent Regulatory Drug Approvals

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Acromegaly and Gigantism Drugs Study Sheds Light on
The Acromegaly and Gigantism Drugs Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Acromegaly and Gigantism Drugs industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
Where Acromegaly and Gigantism Drugs industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.
Report Objectives / Segmentation Covered
By Type
  • Somatostatin Analogs
  • GH Receptor Antagonists
  • Dopamine Agonists
  • Recombinant Human IGF-1
By Distribution Channel
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Chronic Diseases
      • 3.2.2. Increasing Various Hormonal Disorders
      • 3.2.3. Rise in Awareness Among People About Diagnosis of the Disease
    • 3.3. Market Challenges
      • 3.3.1. Stringent Regulatory Drug Approvals
    • 3.4. Market Trends
      • 3.4.1. Growing Popularity of Drugs Over Surgeries
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Acromegaly and Gigantism Drugs, by Type, Distribution Channel and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Acromegaly and Gigantism Drugs (Value)
      • 5.2.1. Global Acromegaly and Gigantism Drugs by: Type (Value)
        • 5.2.1.1. Somatostatin Analogs
        • 5.2.1.2. GH Receptor Antagonists
        • 5.2.1.3. Dopamine Agonists
        • 5.2.1.4. Recombinant Human IGF-1
      • 5.2.2. Global Acromegaly and Gigantism Drugs by: Distribution Channel (Value)
        • 5.2.2.1. Retail Pharmacies
        • 5.2.2.2. Hospital Pharmacies
        • 5.2.2.3. Online Pharmacies
      • 5.2.3. Global Acromegaly and Gigantism Drugs Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Acromegaly and Gigantism Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer Inc (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Chiasma Inc (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Ipsen Pharma (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Johnson and Johnson (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. F. Hoffmann -La Roche Ltd (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Takeda Pharmaceutical Company Limited (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Zydus Pharmaceuticals (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Peptron (South Korea)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Hikma Pharmaceuticals PLC (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Acromegaly and Gigantism Drugs Sale, by Type, Distribution Channel and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Acromegaly and Gigantism Drugs (Value)
      • 7.2.1. Global Acromegaly and Gigantism Drugs by: Type (Value)
        • 7.2.1.1. Somatostatin Analogs
        • 7.2.1.2. GH Receptor Antagonists
        • 7.2.1.3. Dopamine Agonists
        • 7.2.1.4. Recombinant Human IGF-1
      • 7.2.2. Global Acromegaly and Gigantism Drugs by: Distribution Channel (Value)
        • 7.2.2.1. Retail Pharmacies
        • 7.2.2.2. Hospital Pharmacies
        • 7.2.2.3. Online Pharmacies
      • 7.2.3. Global Acromegaly and Gigantism Drugs Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Acromegaly and Gigantism Drugs: by Type(USD Million)
  • Table 2. Acromegaly and Gigantism Drugs Somatostatin Analogs , by Region USD Million (2015-2020)
  • Table 3. Acromegaly and Gigantism Drugs GH Receptor Antagonists , by Region USD Million (2015-2020)
  • Table 4. Acromegaly and Gigantism Drugs Dopamine Agonists , by Region USD Million (2015-2020)
  • Table 5. Acromegaly and Gigantism Drugs Recombinant Human IGF-1 , by Region USD Million (2015-2020)
  • Table 6. Acromegaly and Gigantism Drugs: by Distribution Channel(USD Million)
  • Table 7. Acromegaly and Gigantism Drugs Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 8. Acromegaly and Gigantism Drugs Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 9. Acromegaly and Gigantism Drugs Online Pharmacies , by Region USD Million (2015-2020)
  • Table 10. South America Acromegaly and Gigantism Drugs, by Country USD Million (2015-2020)
  • Table 11. South America Acromegaly and Gigantism Drugs, by Type USD Million (2015-2020)
  • Table 12. South America Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 13. Brazil Acromegaly and Gigantism Drugs, by Type USD Million (2015-2020)
  • Table 14. Brazil Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 15. Argentina Acromegaly and Gigantism Drugs, by Type USD Million (2015-2020)
  • Table 16. Argentina Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 17. Rest of South America Acromegaly and Gigantism Drugs, by Type USD Million (2015-2020)
  • Table 18. Rest of South America Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 19. Asia Pacific Acromegaly and Gigantism Drugs, by Country USD Million (2015-2020)
  • Table 20. Asia Pacific Acromegaly and Gigantism Drugs, by Type USD Million (2015-2020)
  • Table 21. Asia Pacific Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 22. China Acromegaly and Gigantism Drugs, by Type USD Million (2015-2020)
  • Table 23. China Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 24. Japan Acromegaly and Gigantism Drugs, by Type USD Million (2015-2020)
  • Table 25. Japan Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 26. India Acromegaly and Gigantism Drugs, by Type USD Million (2015-2020)
  • Table 27. India Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 28. South Korea Acromegaly and Gigantism Drugs, by Type USD Million (2015-2020)
  • Table 29. South Korea Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 30. Taiwan Acromegaly and Gigantism Drugs, by Type USD Million (2015-2020)
  • Table 31. Taiwan Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 32. Australia Acromegaly and Gigantism Drugs, by Type USD Million (2015-2020)
  • Table 33. Australia Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 34. Rest of Asia-Pacific Acromegaly and Gigantism Drugs, by Type USD Million (2015-2020)
  • Table 35. Rest of Asia-Pacific Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 36. Europe Acromegaly and Gigantism Drugs, by Country USD Million (2015-2020)
  • Table 37. Europe Acromegaly and Gigantism Drugs, by Type USD Million (2015-2020)
  • Table 38. Europe Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 39. Germany Acromegaly and Gigantism Drugs, by Type USD Million (2015-2020)
  • Table 40. Germany Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 41. France Acromegaly and Gigantism Drugs, by Type USD Million (2015-2020)
  • Table 42. France Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 43. Italy Acromegaly and Gigantism Drugs, by Type USD Million (2015-2020)
  • Table 44. Italy Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 45. United Kingdom Acromegaly and Gigantism Drugs, by Type USD Million (2015-2020)
  • Table 46. United Kingdom Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 47. Netherlands Acromegaly and Gigantism Drugs, by Type USD Million (2015-2020)
  • Table 48. Netherlands Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 49. Rest of Europe Acromegaly and Gigantism Drugs, by Type USD Million (2015-2020)
  • Table 50. Rest of Europe Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 51. MEA Acromegaly and Gigantism Drugs, by Country USD Million (2015-2020)
  • Table 52. MEA Acromegaly and Gigantism Drugs, by Type USD Million (2015-2020)
  • Table 53. MEA Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 54. Middle East Acromegaly and Gigantism Drugs, by Type USD Million (2015-2020)
  • Table 55. Middle East Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 56. Africa Acromegaly and Gigantism Drugs, by Type USD Million (2015-2020)
  • Table 57. Africa Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 58. North America Acromegaly and Gigantism Drugs, by Country USD Million (2015-2020)
  • Table 59. North America Acromegaly and Gigantism Drugs, by Type USD Million (2015-2020)
  • Table 60. North America Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 61. United States Acromegaly and Gigantism Drugs, by Type USD Million (2015-2020)
  • Table 62. United States Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 63. Canada Acromegaly and Gigantism Drugs, by Type USD Million (2015-2020)
  • Table 64. Canada Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 65. Mexico Acromegaly and Gigantism Drugs, by Type USD Million (2015-2020)
  • Table 66. Mexico Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Acromegaly and Gigantism Drugs: by Type(USD Million)
  • Table 78. Acromegaly and Gigantism Drugs Somatostatin Analogs , by Region USD Million (2021-2026)
  • Table 79. Acromegaly and Gigantism Drugs GH Receptor Antagonists , by Region USD Million (2021-2026)
  • Table 80. Acromegaly and Gigantism Drugs Dopamine Agonists , by Region USD Million (2021-2026)
  • Table 81. Acromegaly and Gigantism Drugs Recombinant Human IGF-1 , by Region USD Million (2021-2026)
  • Table 82. Acromegaly and Gigantism Drugs: by Distribution Channel(USD Million)
  • Table 83. Acromegaly and Gigantism Drugs Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 84. Acromegaly and Gigantism Drugs Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 85. Acromegaly and Gigantism Drugs Online Pharmacies , by Region USD Million (2021-2026)
  • Table 86. South America Acromegaly and Gigantism Drugs, by Country USD Million (2021-2026)
  • Table 87. South America Acromegaly and Gigantism Drugs, by Type USD Million (2021-2026)
  • Table 88. South America Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 89. Brazil Acromegaly and Gigantism Drugs, by Type USD Million (2021-2026)
  • Table 90. Brazil Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 91. Argentina Acromegaly and Gigantism Drugs, by Type USD Million (2021-2026)
  • Table 92. Argentina Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 93. Rest of South America Acromegaly and Gigantism Drugs, by Type USD Million (2021-2026)
  • Table 94. Rest of South America Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 95. Asia Pacific Acromegaly and Gigantism Drugs, by Country USD Million (2021-2026)
  • Table 96. Asia Pacific Acromegaly and Gigantism Drugs, by Type USD Million (2021-2026)
  • Table 97. Asia Pacific Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 98. China Acromegaly and Gigantism Drugs, by Type USD Million (2021-2026)
  • Table 99. China Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 100. Japan Acromegaly and Gigantism Drugs, by Type USD Million (2021-2026)
  • Table 101. Japan Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 102. India Acromegaly and Gigantism Drugs, by Type USD Million (2021-2026)
  • Table 103. India Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 104. South Korea Acromegaly and Gigantism Drugs, by Type USD Million (2021-2026)
  • Table 105. South Korea Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 106. Taiwan Acromegaly and Gigantism Drugs, by Type USD Million (2021-2026)
  • Table 107. Taiwan Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 108. Australia Acromegaly and Gigantism Drugs, by Type USD Million (2021-2026)
  • Table 109. Australia Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 110. Rest of Asia-Pacific Acromegaly and Gigantism Drugs, by Type USD Million (2021-2026)
  • Table 111. Rest of Asia-Pacific Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 112. Europe Acromegaly and Gigantism Drugs, by Country USD Million (2021-2026)
  • Table 113. Europe Acromegaly and Gigantism Drugs, by Type USD Million (2021-2026)
  • Table 114. Europe Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 115. Germany Acromegaly and Gigantism Drugs, by Type USD Million (2021-2026)
  • Table 116. Germany Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 117. France Acromegaly and Gigantism Drugs, by Type USD Million (2021-2026)
  • Table 118. France Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 119. Italy Acromegaly and Gigantism Drugs, by Type USD Million (2021-2026)
  • Table 120. Italy Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 121. United Kingdom Acromegaly and Gigantism Drugs, by Type USD Million (2021-2026)
  • Table 122. United Kingdom Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 123. Netherlands Acromegaly and Gigantism Drugs, by Type USD Million (2021-2026)
  • Table 124. Netherlands Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 125. Rest of Europe Acromegaly and Gigantism Drugs, by Type USD Million (2021-2026)
  • Table 126. Rest of Europe Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 127. MEA Acromegaly and Gigantism Drugs, by Country USD Million (2021-2026)
  • Table 128. MEA Acromegaly and Gigantism Drugs, by Type USD Million (2021-2026)
  • Table 129. MEA Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 130. Middle East Acromegaly and Gigantism Drugs, by Type USD Million (2021-2026)
  • Table 131. Middle East Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 132. Africa Acromegaly and Gigantism Drugs, by Type USD Million (2021-2026)
  • Table 133. Africa Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 134. North America Acromegaly and Gigantism Drugs, by Country USD Million (2021-2026)
  • Table 135. North America Acromegaly and Gigantism Drugs, by Type USD Million (2021-2026)
  • Table 136. North America Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 137. United States Acromegaly and Gigantism Drugs, by Type USD Million (2021-2026)
  • Table 138. United States Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 139. Canada Acromegaly and Gigantism Drugs, by Type USD Million (2021-2026)
  • Table 140. Canada Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 141. Mexico Acromegaly and Gigantism Drugs, by Type USD Million (2021-2026)
  • Table 142. Mexico Acromegaly and Gigantism Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 143. Research Programs/Design for This Report
  • Table 144. Key Data Information from Secondary Sources
  • Table 145. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Acromegaly and Gigantism Drugs: by Type USD Million (2015-2020)
  • Figure 5. Global Acromegaly and Gigantism Drugs: by Distribution Channel USD Million (2015-2020)
  • Figure 6. South America Acromegaly and Gigantism Drugs Share (%), by Country
  • Figure 7. Asia Pacific Acromegaly and Gigantism Drugs Share (%), by Country
  • Figure 8. Europe Acromegaly and Gigantism Drugs Share (%), by Country
  • Figure 9. MEA Acromegaly and Gigantism Drugs Share (%), by Country
  • Figure 10. North America Acromegaly and Gigantism Drugs Share (%), by Country
  • Figure 11. Global Acromegaly and Gigantism Drugs share by Players 2020 (%)
  • Figure 12. Global Acromegaly and Gigantism Drugs share by Players (Top 3) 2020(%)
  • Figure 13. Global Acromegaly and Gigantism Drugs share by Players (Top 5) 2020(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Pfizer Inc (United States) Revenue, Net Income and Gross profit
  • Figure 16. Pfizer Inc (United States) Revenue: by Geography 2020
  • Figure 17. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 19. Chiasma Inc (United States) Revenue, Net Income and Gross profit
  • Figure 20. Chiasma Inc (United States) Revenue: by Geography 2020
  • Figure 21. Ipsen Pharma (France) Revenue, Net Income and Gross profit
  • Figure 22. Ipsen Pharma (France) Revenue: by Geography 2020
  • Figure 23. Johnson and Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 24. Johnson and Johnson (United States) Revenue: by Geography 2020
  • Figure 25. F. Hoffmann -La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. F. Hoffmann -La Roche Ltd (Switzerland) Revenue: by Geography 2020
  • Figure 27. Takeda Pharmaceutical Company Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 28. Takeda Pharmaceutical Company Limited (Japan) Revenue: by Geography 2020
  • Figure 29. Zydus Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 30. Zydus Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 31. Peptron (South Korea) Revenue, Net Income and Gross profit
  • Figure 32. Peptron (South Korea) Revenue: by Geography 2020
  • Figure 33. Hikma Pharmaceuticals PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. Hikma Pharmaceuticals PLC (United Kingdom) Revenue: by Geography 2020
  • Figure 35. Global Acromegaly and Gigantism Drugs: by Type USD Million (2021-2026)
  • Figure 36. Global Acromegaly and Gigantism Drugs: by Distribution Channel USD Million (2021-2026)
  • Figure 37. South America Acromegaly and Gigantism Drugs Share (%), by Country
  • Figure 38. Asia Pacific Acromegaly and Gigantism Drugs Share (%), by Country
  • Figure 39. Europe Acromegaly and Gigantism Drugs Share (%), by Country
  • Figure 40. MEA Acromegaly and Gigantism Drugs Share (%), by Country
  • Figure 41. North America Acromegaly and Gigantism Drugs Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Pfizer Inc (United States)
  • Novartis AG (Switzerland)
  • Chiasma Inc (United States)
  • Ipsen Pharma (France)
  • Johnson and Johnson (United States)
  • F. Hoffmann -La Roche Ltd (Switzerland)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Zydus Pharmaceuticals (United States)
  • Peptron (South Korea)
  • Hikma Pharmaceuticals PLC (United Kingdom)
Additional players considered in the study are as follows:
Midatec Pharma Plc (United Kingdom) , Crinetics Pharmaceuticals (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation